200 related articles for article (PubMed ID: 32072585)
21. An Empirical Analysis of Japan's Drug Development Lag Behind the United States.
Nakamura H; Wakutsu N; Murayama S; Suzuki T
J Clin Pharmacol; 2022 Jul; 62(7):847-854. PubMed ID: 34970781
[TBL] [Abstract][Full Text] [Related]
22. Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval.
Harada K; Toriyabe K; Ono S
J Clin Pharmacol; 2020 Jan; 60(1):117-124. PubMed ID: 31364772
[TBL] [Abstract][Full Text] [Related]
23. Trends in oncology drug lags in Japan from 2001 to 2020: A cross-sectional study.
Maeda H; Hara A; Ofuchi M; Shingai R; Misumi T; Murai Y
Clin Transl Sci; 2023 Dec; 16(12):2665-2674. PubMed ID: 37815272
[TBL] [Abstract][Full Text] [Related]
24. Drug approval delays in hematologic malignancies between Europe and the US and between Japan and the US: a clinical perspective.
Matsuda K; Nagai S; Sugimoto K
Jpn J Clin Oncol; 2023 Dec; 53(12):1125-1129. PubMed ID: 37642224
[TBL] [Abstract][Full Text] [Related]
25. A Significant Anticancer Drug Approval Lag Between Japan and the United States Still Exists for Minor Cancers.
Yamashita K; Kaneko M; Narukawa M
Clin Pharmacol Ther; 2019 Jan; 105(1):153-160. PubMed ID: 29882302
[TBL] [Abstract][Full Text] [Related]
26. Regulatory review time for approval of oncology drugs in Japan between 2001 and 2014. Considerations of changes, factors that affect review time, and difference with the United States.
Maeda H; Kurokawa T
J Clin Pharmacol; 2015 May; 55(5):481-9. PubMed ID: 25560978
[TBL] [Abstract][Full Text] [Related]
27. Consistency of listed indications and contraindications between the U.S., the U.K., Japan, and Korea on prescription drug labels.
Yoon D; Song I; Noh Y; Li J; Shin JY
Regul Toxicol Pharmacol; 2018 Oct; 98():168-170. PubMed ID: 30056245
[TBL] [Abstract][Full Text] [Related]
28. Relationship between drug lag and factors associated with clinical trials in Japan.
Ohwaki K; Nakabayashi T
J Clin Pharm Ther; 2014 Dec; 39(6):649-52. PubMed ID: 25200123
[TBL] [Abstract][Full Text] [Related]
29. Access to Innovative Medicines: Regulation Change and Factors Associated with Drug Approval Lag in Malaysia.
Chow WL; Salleh NAM; Kang TS
Ther Innov Regul Sci; 2024 May; 58(3):528-538. PubMed ID: 38376698
[TBL] [Abstract][Full Text] [Related]
30. Delays in psychiatric drug development in Japan.
Shimazawa R; Kusumi I; Ikeda M
J Clin Pharm Ther; 2012 Jun; 37(3):348-51. PubMed ID: 22017294
[TBL] [Abstract][Full Text] [Related]
31. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
Shimazawa R; Ikeda M
Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
[TBL] [Abstract][Full Text] [Related]
32. How can we improve patients' access to new drugs under uncertainties? : South Korea's experience with risk sharing arrangements.
Lee B; Bae EY; Bae S; Choi HJ; Son KB; Lee YS; Jang S; Lee TJ
BMC Health Serv Res; 2021 Sep; 21(1):967. PubMed ID: 34521408
[TBL] [Abstract][Full Text] [Related]
33. Drug lag for cardiovascular drug approvals in India compared with the US and EU approvals.
Kataria BC; Mehta DS; Chhaiya SB
Indian Heart J; 2013; 65(1):24-9. PubMed ID: 23438609
[TBL] [Abstract][Full Text] [Related]
34. An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004-2018).
Konwar M; Maurya MR; Nishandar TB; Thatte UM; Gogtay NJ
Perspect Clin Res; 2021; 12(3):159-164. PubMed ID: 34386381
[TBL] [Abstract][Full Text] [Related]
35. Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications.
Kwon HY; Kim H; Godman B
Front Pharmacol; 2018; 9():938. PubMed ID: 30233363
[No Abstract] [Full Text] [Related]
36. Increasing orphan drug loss in Japan: Trends and R&D strategy for rare diseases.
Enya K; Lim Y; Sengoku S; Kodama K
Drug Discov Today; 2023 Oct; 28(10):103755. PubMed ID: 37648019
[TBL] [Abstract][Full Text] [Related]
37. Assessment of the Delay in Novel Anticancer Drugs between China and the United States: A Comparative Study of Drugs Approved between 2010 and 2021.
Luo X; Du X; Li Z; Qian F; Yang Y
Clin Pharmacol Ther; 2023 Jan; 113(1):170-181. PubMed ID: 36151921
[TBL] [Abstract][Full Text] [Related]
38. Recent trends and success factors in reducing the lag time to approval of new drugs in Japan.
Honig PK
Clin Pharmacol Ther; 2014 May; 95(5):467-9. PubMed ID: 24747231
[TBL] [Abstract][Full Text] [Related]
39. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations.
Tsuji K; Tsutani K
Eur J Pharm Biopharm; 2008 Mar; 68(3):496-502. PubMed ID: 17884403
[TBL] [Abstract][Full Text] [Related]
40. Matched analysis on orphan drug designations and approvals: cross regional analysis in the United States, the European Union, and Japan.
Murakami M; Narukawa M
Drug Discov Today; 2016 Apr; 21(4):544-9. PubMed ID: 26945941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
